Neuro-oncology clinical trials: promise and pitfalls

Free article

Editorial

M R Gilbert. Ann Oncol. 2001 Feb.

Free article

. 2001 Feb;12(2):149-50.

doi: 10.1093/oxfordjournals.annonc.a000239.

No abstract available

Comment on

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV; Hellenic Cooperative Oncology Group. Christodoulou C, et al. Ann Oncol. 2001 Feb;12(2):249-54. doi: 10.1023/a:1008354323167. Ann Oncol. 2001. PMID: 11300333 Clinical Trial.
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Brandes AA, et al. Ann Oncol. 2001 Feb;12(2):255-7. doi: 10.1023/a:1008336732273. Ann Oncol. 2001. PMID: 11300334 Clinical Trial.
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S. Brada M, et al. Ann Oncol. 2001 Feb;12(2):259-66. doi: 10.1023/a:1008382516636. Ann Oncol. 2001. PMID: 11300335 Clinical Trial.